<DOC>
	<DOCNO>NCT00241449</DOCNO>
	<brief_summary>The purpose study compare efficacy Faslodex ( fulvestrant ) Nolvadex ( tamoxifen ) first-line treatment postmenopausal woman advance breast cancer . Patients treat disease progression investigator determine treatment best interest patient , whichever occur first .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Tolerability Faslodex With Nolvadex Postmenopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Biopsy confirmation breast cancer . Evidence breast cancer consider amenable curative treatment . Postmenopausal woman . Written inform consent participate study . Previous treatment hormonal therapy unless therapy tamoxifen adjuvant breast cancer . The use tamoxifen must cease least one year study . Previous treatment Faslodex . Any exist serious disease , illness , condition prevent participation compliance study procedure . Treatment investigational nonapproved drug within one month start study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Locally advanced breast cancer metastatic breast cancer</keyword>
</DOC>